CSS
INMB icon

Cubist Systematic Strategies’s INmune Bio INMB Stock Holding History

Cubist Systematic Strategies’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,743
Closed -$61.8K – 3253
2025
Q2 		$61.8K Buy
+26,743
New +$196K ﹤0.01% 2764
2024
Q2 		– Sell
-4,782
Closed -$56.2K – 3467
2024
Q1 		$56.2K Buy
+4,782
New +$57.8K ﹤0.01% 3362
2021
Q4 		– Sell
-19,989
Closed -$388K – 3537
2021
Q3 		$388K Buy
+19,989
New +$386K ﹤0.01% 2197
2020
Q4 		– Sell
-1,000
Closed -$10K – 2624
2020
Q3 		$10K Buy
+1,000
New +$10.2K ﹤0.01% 2434

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's INMB Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 26,743 shares — an estimated $61.8K sold.

Cubist Systematic Strategies first reported a position in INMB in Q3 2020 and held it in 4 quarters. The position peaked at $388K in Q3 2021. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 26,743 INmune Bio shares in Q3 2025, an estimated $61.8K.
  • Cubist Systematic Strategies first reported a position in INmune Bio in Q3 2020 and held it in 4 quarters.
  • Cubist Systematic Strategies's INmune Bio position peaked at $388K in Q3 2021.
  • 73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.